Literature DB >> 15913472

Trials of gene therapy for pancreatic carcinoma.

Christopher M Halloran1, Paula Ghaneh, Eithne Costello, John P Neoptolemos.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 15913472     DOI： 10.1007/s11894-005-0028-7

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN： 1522-8037


× No keyword cloud information.
  64 in total

1.  Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo.

Authors:  P Ghaneh; W Greenhalf; M Humphreys; D Wilson; L Zumstein; N R Lemoine; J P Neoptolemos
Journal:  Gene Ther       Date:  2001-02       Impact factor: 5.250

2.  Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma.

Authors:  M Löhr; A Hoffmeyer; J Kröger; M Freund; J Hain; A Holle; P Karle; W T Knöfel; S Liebe; P Müller; H Nizze; M Renner; R M Saller; T Wagner; K Hauenstein; W H Günzburg; B Salmons
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

3.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

4.  The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice.

Authors:  M Takeuchi; T Shichinohe; N Senmaru; M Miyamoto; H Fujita; M Takimoto; S Kondo; H Katoh; N Kuzumaki
Journal:  Gene Ther       Date:  2000-03       Impact factor: 5.250

Review 5.  Complications of pancreatic cancer resection.

Authors:  C M Halloran; P Ghaneh; L Bosonnet; M N Hartley; R Sutton; J P Neoptolemos
Journal:  Dig Surg       Date:  2002       Impact factor: 2.588

6.  Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors.

Authors:  Bruno Sangro; Guillermo Mazzolini; Juan Ruiz; Maite Herraiz; Jorge Quiroga; Ignacio Herrero; Alberto Benito; Javier Larrache; Jesus Pueyo; Jose Carlos Subtil; Cristina Olagüe; Josu Sola; Belén Sádaba; Carlos Lacasa; Ignacio Melero; Cheng Qian; Jesus Prieto
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

7.  Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region.

Authors:  J H Allema; M E Reinders; T M van Gulik; M J Koelemay; D J Van Leeuwen; L T de Wit; D J Gouma; H Obertop
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

8.  Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer.

Authors:  Kazuteru Hatanaka; Koichi Suzuki; Yoshiaki Miura; Kimiko Yoshida; Shumpei Ohnami; Yukio Kitade; Teruhiko Yoshida; Kazunori Aoki
Journal:  J Gene Med       Date:  2004-10       Impact factor: 4.565

9.  Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation.

Authors:  Eduard Ryschich; Ralf Jesnowski; Jörg Ringel; Walter Harms; Oliver V Fabian; Robert Saller; Michael Schrewe; Alexander Engel; Jan Schmidt; Matthias Löhr
Journal:  Int J Cancer       Date:  2005-02-10       Impact factor: 7.396

10.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase.

Authors:  B E Huber; E A Austin; C A Richards; S T Davis; S S Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.